NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0704126/Gallbladder-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary GlobalData, the industry analysis specialist, has released its new report, "Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Gallbladder Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Gallbladder Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gallbladder Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Scope The report provides information on the key drivers and challenges of the Gallbladder Cancer Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gallbladder Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Gallbladder Cancer Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gallbladder Cancer Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Gallbladder Cancer Therapeutics market

Reasons to buy The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Gallbladder Cancer Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gallbladder Cancer Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Gallbladder Cancer Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 52 Gallbladder Cancer Therapeutics - Introduction 62.1 Overview 62.2 Epidemiology 72.3 Etiology 72.4 Pathophysiology 82.5 Signs and Symptoms 82.6 Diagnosis 82.6.1 Physical exam and history 82.6.2 Ultrasound exam 82.6.3 Liver function tests 82.6.4 Carcinoembryonic antigen (CEA) assay 82.6.5 Cancer antigen 19-9 (CA 19-9) assay 82.6.6 CT scan (CAT scan) 92.6.7 Blood chemistry studies 92.6.8 Chest x-ray 92.6.9 MRI (magnetic resonance imaging) 92.6.10 ERCP (Endoscopic Retrograde Cholangiopancreatography) 92.6.11 Biopsy 92.6.12 Laparoscopy 92.6.13 PTC (Percutaneous Transhepatic Cholangiography) 102.7 Staging 102.7.1 TNM Classification 102.7.2 Treatment Options Based on the Extent of Cancer 112.8 Treatment 112.8.1 Surgery 122.8.2 Chemotherapy 122.8.3 Radiation therapy (RT) 122.9 Chemotherapy Regimens 122.10 GlobalData Pipeline Report Guidance 133 Gallbladder Cancer Therapeutics - Market Characterization 143.1 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Global 143.2 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Global 163.3 Gallbladder Cancer Therapeutics Market Size (2005-2010) - US 183.4 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - The US 193.5 Gallbladder Cancer Therapeutics Market Size (2005-2010) - The UK 203.6 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - The UK 213.7 Gallbladder Cancer Therapeutics Market Size (2005-2010) - France 223.8 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - France 233.9 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Germany 243.10 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Germany 253.11 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Italy 263.12 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Italy 273.13 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Spain 283.14 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Spain 293.15 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Japan 303.16 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Japan 313.17 Drivers and Barriers for the Gallbladder Cancer Therapeutics Market 323.17.1 Drivers for the Gallbladder Cancer Therapeutics Market 323.17.2 Barriers for the Gallbladder Cancer Therapeutics Market 323.18 Key Events Impacting the Future Market 333.18.1 Opportunity and Unmet Need 333.19 Key Takeaway 344 Gallbladder Cancer Therapeutics Market - Competitive Assessment 354.1 Overview 354.1.1 Strategic Competitor Assessment 354.2 Profiles of the Commonly Used Products in the Gallbladder Cancer Therapeutics Market 364.2.1 Gemcitabine 364.2.2 Gemcitabine and Cisplatin 364.2.3 Gemcitabine and Oxaliplatin (GEMOX) 364.2.4 Gemcitabine and Capecitabine 364.2.5 5-Fluorouracil (5-FU) and Cisplatin 364.3 Key Takeaway 375 Gallbladder Cancer Therapeutics Market - Pipeline Assessment 385.1 Overview 385.2 Strategic Pipeline Assessment 385.3 Gallbladder Cancer Pipeline Analysis - Pipeline by Clinical Phases of Development 385.3.1 Gallbladder Cancer Therapeutics - Phase II Pipeline 395.3.2 Gallbladder Cancer Therapeutics - Phase I/II Pipeline 395.3.3 Gallbladder Cancer Therapeutics - Phase I Pipeline 395.4 Gallbladder Cancer Pipeline by Mechanism of Action 405.5 Gallbladder Cancer Technology Trends Analytical Framework 415.6 Profiles of Phase II Drugs under Clinical Development 425.6.1 Caprelsa (vandetanib) 425.6.2 Sinofuan (fluorouracil implant) 425.7 Key Takeaway 426 Gallbladder Cancer Therapeutics - Clinical Trials Mapping 436.1 Clinical Trials by Country (US, EU5 and Japan) 436.2 Clinical Trials Mapping by Phase 446.3 Clinical Trials Mapping by Trial Status 456.4 Overall Sponsors 466.5 Prominent Sponsors 476.6 Top Companies Participating in Gallbladder Cancer Therapeutics Clinical Trials 487 Gallbladder Cancer Therapeutics - Strategic Assessment 497.1 Future Market Competition Scenario 498 Gallbladder Cancer Therapeutics - Future Players in The Market 508.1 Introduction 508.2 Company Profiles 518.2.1 AstraZeneca PLC 518.2.2 Simcere Pharmaceutical Co. Ltd. 529 Gallbladder Cancer Therapeutics- Appendix 549.1 Definitions 549.2 Acronyms 549.3 Research Methodology 559.3.1 Coverage 559.3.2 Secondary Research 569.3.3 Forecasting 569.3.4 Primary Research 589.3.5 Expert Panel Validation 599.4 Contact Us 599.5 Disclaimer 599.6 Bibliography 59

List of Tables

Table 1: Survival Rates of Gallbladder Cancer in Various Stages 7Table 2: Prevalence of Gallbladder Cancer in Major Markets 7Table 3: Gallbladder Cancer, TNM Definitions 10Table 4: Gallbladder Cancer, Stage Grouping 11Table 5: Treatment Options Based on the Extent of Cancer 11Table 6: Gallbladder Cancer Chemotherapy regimens 12Table 7: Gallbladder Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010 14Table 8: Gallbladder Cancer Therapeutics Market, Global, Forecast ($m), 2010-2018 16Table 9: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010 18Table 10: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2010-2018 19Table 11: Gallbladder Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010 20Table 12: Gallbladder Cancer Therapeutics Market, The UK, Forecast ($m), 2010-2018 21Table 13: Gallbladder Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 22Table 14: Gallbladder Cancer Therapeutics Market, France, Forecast ($m), 2010-2018 23Table 15: Gallbladder Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 24Table 16: Gallbladder Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018 25Table 17: Gallbladder Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 26Table 18: Gallbladder Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2018 27Table 19: Gallbladder Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 28Table 20: Gallbladder Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018 29Table 21: Gallbladder Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 30Table 22: Gallbladder Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018 31Table 23: Gallbladder Cancer - Phase II Pipeline 39Table 24: Gallbladder Cancer Therapeutics - Phase I/II Pipeline 39Table 25: Gallbladder Cancer Therapeutics - Phase I Pipeline 39Table 26: Gallbladder Cancer Therapeutics - Clinical Trials by Country, 2011 43Table 27: Gallbladder Cancer Therapeutics - Clinical Trials by Phase, 2011 44Table 28: Gallbladder Cancer Therapeutics - Clinical Trials by Status, 2011 45Table 29: Gallbladder Cancer Therapeutics - Clinical Trials, by Overall Sponsors, 2011 46Table 30: Gallbladder Cancer Therapeutics - Clinical Trials by Prominent Sponsors, 2011 47Table 31: Gallbladder Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 48Table 32: AstraZeneca - Gallbladder Cancer Pipeline 52Table 33: Simcere Pharmaceutical - Gallbladder Cancer Pipeline 53

List of Figures

Figure 1: Anatomy of the Gallbladder 6Figure 2: Magnetic Resonance Imaging 9Figure 3: Gallbladder Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010 14Figure 4: Gallbladder Cancer Therapeutics, Market Share ($m), 2010 15Figure 5: Gallbladder Cancer Therapeutics Market, Global, Forecast ($m), 2010-2018 16Figure 6: Gallbladder Cancer Therapeutics, Market Share ($m), 2018 17Figure 7: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010 18Figure 8: Gallbladder Cancer Therapeutics Market, The US, Forecast ($m), 2010-2018 19Figure 9: Gallbladder Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010 20Figure 10: Gallbladder Cancer Therapeutics, The UK, Forecast ($m), 2010-2018 21Figure 11: Gallbladder Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 22Figure 12: Gallbladder Cancer Therapeutics Market, France, Forecast ($m), 2010-2018 23Figure 13: Gallbladder Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 24Figure 14: Gallbladder Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018 25Figure 15: Gallbladder Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 26Figure 16: Gallbladder Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2018 27Figure 17: Gallbladder Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 28Figure 18: Gallbladder Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018 29Figure 19: Gallbladder Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 30Figure 20: Gallbladder Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018 31Figure 21: Gallbladder Cancer Therapeutics, Key Events Impacting the Future Market 33Figure 22: Opportunity and Unmet Need in the Gallbladder Cancer Therapeutics Market, 2011 34Figure 23: Gallbladder Cancer Therapeutics Market- Strategic Competitor Assessment, 2011 35Figure 24: Gallbladder Cancer Therapeutics - Pipeline by Phase of Clinical Development, 2011 38Figure 25: Gallbladder Cancer Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011 40Figure 26: Gallbladder Cancer Therapeutics - Technology Trends Analytical Framework, 2011 41Figure 27: Gallbladder Cancer Therapeutics - Technology Trends Analytical Framework - Description, 2011 41Figure 28: Gallbladder Cancer Therapeutics - Clinical Trials by Country, 2011 43Figure 29: Gallbladder Cancer Therapeutics - Clinical Trials by Phase, 2011 44Figure 30: Gallbladder Cancer Therapeutics - Clinical Trials by Status, 2011 45Figure 31: Gallbladder Cancer Therapeutics - Clinical Trials by Overall Sponsors, 2011 46Figure 32: Gallbladder Cancer Therapeutics - Clinical trials by Prominent Sponsors, 2011 47Figure 33: Gallbladder Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 48Figure 34: Gallbladder Cancer Therapeutics, Strategic Assessment, 2011 49Figure 35: Gallbladder Cancer Therapeutics Market - Clinical Pipeline by Company , 2011 50Figure 36: GlobalData Market Forecasting Model 58

Companies mentioned

AstraZeneca PLCSimcere Pharmaceutical Co. Ltd.To order this report:Therapy Industry: Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018More  Market Research ReportCheck our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com